DUSP1, BUB1 and MCM7-based endometrial cancer prognosis evaluation model and application thereof

By detecting the expression levels of BUB1, DUSP1, and MCM7 and combining them with a tumor staging and grading prognostic assessment model for endometrial cancer, the problem of existing classification models being unable to accurately predict prognosis has been solved, enabling precise assessment and individualized treatment guidance for endometrial cancer patients.

CN122290725APending Publication Date: 2026-06-26PEOPLES HOSPITAL PEKING UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202610216271.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-14
Publication Date
2026-06-26

AI Technical Summary

Technical Problem

Existing classification models for endometrial cancer cannot accurately predict patient prognosis, leading to overtreatment or undertreatment. Traditional pathological morphological diagnosis cannot meet the needs of modern medicine, and TCGA molecular classification faces difficulties in clinical application.

Method used

This invention provides a prognostic assessment model for endometrial cancer based on the expression levels of BUB1, DUSP1, and MCM7, including a prognostic risk scoring model and a total score model. By detecting the expression levels of these genes and combining them with tumor staging and grading data, the model calculates scores and predicts patients' recurrence-free survival and overall survival.

Benefits of technology

It enables precise prognostic assessment of endometrial cancer patients, reduces the risk of overtreatment, provides individualized treatment guidance, and improves the accuracy of prognostic prediction.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an endometrial cancer prognosis evaluation model based on DUSP1, BUB1 and MCM7 and application of the endometrial cancer prognosis evaluation model. The endometrial cancer prognosis evaluation model comprises an endometrial cancer prognosis risk scoring model and an endometrial cancer prognosis total scoring model, and the endometrial cancer prognosis risk scoring model comprises a recurrence-free survival risk scoring model and a total survival risk scoring model; the endometrial cancer prognosis total score model comprises a recurrence-free survival total score model and a total survival total score model. Experiments prove that the recurrence-free survival rate and the total survival rate of endometrial cancer patients can be effectively predicted based on the endometrial cancer prognosis evaluation models. The endometrial cancer prognosis evaluation model provided by the invention is beneficial to hierarchical management of endometrial cancer patients, reduces excessive treatment, accurately predicts relapse, and provides theoretical and clinical basis for guiding clinical individualized treatment of the endometrial cancer patients.
Need to check novelty before this filing date? Find Prior Art